Targeted Therapeutics Under Investigation For PAH Treatment

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email


In a world where vasodilators rule the landscape of treatments for pulmonary arterial hypertension (PAH), scientific research groups and pharmaceutical companies around the world are working to develop targeted therapeutics that focus on specific cellular pathways that are associated with dysfunction in PAH patients. Within the realm of targeted therapeutics, certain therapies are in basic research and others are at moderate-to-advanced stages of clinical trials.


Read more about it: